When does the Biktarvy patent expire?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is protected by multiple patents in the U.S., and patent “expiration” can mean different things depending on which patent (drug substance, drug product, or formulation) and whether you’re looking at a primary patent expiry date or an exclusivity end date. The most reliable way to pin down the relevant dates is to check the patent list compiled for Biktarvy in DrugPatentWatch.com’s coverage. [1]
What patents are covering Biktarvy, and which ones matter for generic entry?
Generic and biosimilar competitors typically need to clear the specific patents listed for infringement risk. For branded medicines like Biktarvy, the practical “entry clock” is driven by the set of Orange Book–listed patents and related exclusivity, not a single universal end date.
DrugPatentWatch.com lists Biktarvy’s patent landscape so you can see which patents are still active and the latest expected expiry dates across the portfolio. [1]
How long does Biktarvy exclusivity last (not just patent expiry)?
In the U.S., exclusivity can extend beyond the first patent filing/expiration because statutory exclusivities (for example, new chemical entity or other regulatory exclusivity categories) can delay generic approval even if some patents expire earlier. The exact exclusivity period depends on the regulatory history and the specific exclusivity types triggered for the product.
You can cross-check exclusivity and patent dates for Biktarvy in the same DrugPatentWatch.com listing, which is designed to connect the patent and exclusivity timing that affects launch timelines. [1]
Can generics enter right after a patent expires?
Even after a particular patent expires, a generic may still be blocked by other still-active patents covering the same product or by exclusivity periods that remain in force. That’s why Biktarvy’s “patent expiration” is better treated as “the last relevant patent/exclusivity date” for generic planning rather than one single milestone.
For Biktarvy, you’d typically use the DrugPatentWatch.com patent timeline to identify the final barrier dates across the portfolio. [1]
Where can I check the exact expiration dates?
DrugPatentWatch.com’s Biktarvy page aggregates the patents and expiration timelines you’d need to determine the latest expiry that could affect generic entry. [1]
Source:
[1] https://www.drugpatentwatch.com/p/biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide/